Marker Therapeutics (MRKR) Accounts Payables (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Accounts Payables of $1.9 million for Q1 2026, down 8.44% year-over-year from $2.1 million in Q1 2025, and up 47.28% quarter-over-quarter from $1.3 million in Q4 2025.
Marker Therapeutics (MRKR) Accounts Payables (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Accounts Payables for 17 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 8.44% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 8.44% YoY), while the FY2025 annual figure was $1.3 million, down 25.92% from the prior year.
- Accounts Payables grew to $1.9 million in Q1 2026 per MRKR's latest filing, from $1.3 million in the prior quarter.
- Across five years, Accounts Payables topped out at $7.3 million in Q1 2022 and bottomed at $1.3 million in Q4 2025.
- Historically, Accounts Payables has averaged $2.8 million across 5 years, with a median of $2.1 million in 2025.
- On a YoY basis, Accounts Payables climbed as much as 100.03% in 2022 and fell as far as 77.36% in 2022.
- Marker Therapeutics' Accounts Payables stood at $2.5 million in 2022, then tumbled by 30.78% to $1.7 million in 2023, then gained by 0.5% to $1.8 million in 2024, then slipped by 25.92% to $1.3 million in 2025, then surged by 47.28% to $1.9 million in 2026.
- Business Quant data shows MRKR's Accounts Payables at $1.9 million in Q1 2026, $1.3 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | 1.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.91 Mn |
| Dec 31, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.66 Mn |
| Jun 30, 2025 | 2.27 Mn |
| Mar 31, 2025 | 2.09 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Sep 30, 2024 | 2.56 Mn |
| Jun 30, 2024 | 1.68 Mn |
| Mar 31, 2024 | 1.95 Mn |
| Dec 31, 2023 | 1.75 Mn |
| Sep 30, 2023 | 2.30 Mn |
| Jun 30, 2023 | 1.33 Mn |
| Mar 31, 2023 | 4.54 Mn |
| Dec 31, 2022 | 2.52 Mn |
| Sep 30, 2022 | 5.75 Mn |
| Jun 30, 2022 | 4.74 Mn |
| Mar 31, 2022 | 7.35 Mn |
| Dec 31, 2021 | 11.13 Mn |
| Sep 30, 2021 | 7.65 Mn |
| Jun 30, 2021 | 5.10 Mn |